$1.1
Market Capitalization | 116.1M |
Book Value | $0.56 |
Earnings Per Share (EPS) | -0.14 |
Wall Street Target Price | 1.1 |
Profit Margin | -14.03% |
Operating Margin TTM | 2.73% |
Return On Assets TTM | -1.44% |
Return On Equity TTM | -22.4% |
Revenue TTM | 94.6M |
Revenue Per Share TTM | 0.99 |
Quarterly Revenue Growth YOY | 14.2% |
Gross Profit TTM | 23.1M |
EBITDA | 5.3M |
Diluted Eps TTM | -0.14 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.09 |
EPS Estimate Next Year | -0.06 |
EPS Estimate Current Quarter | -0.01 |
EPS Estimate Next Quarter | 0.0 |
What analysts predicted
Upside of 0.0%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 77.3M | ↑ 7.67% |
Net Income | -79.7M | ↑ 59.19% |
Net Profit Margin | -103.07% | ↓ 33.35% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 99.2M | ↑ 28.28% |
Net Income | -38.4M | ↓ 51.79% |
Net Profit Margin | -38.74% | ↑ 64.33% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 66.5M | ↓ 32.98% |
Net Income | -46.7M | ↑ 21.4% |
Net Profit Margin | -70.17% | ↓ 31.43% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 75.4M | ↑ 13.33% |
Net Income | -26.5M | ↓ 43.2% |
Net Profit Margin | -35.17% | ↑ 35.0% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 90.2M | ↑ 19.71% |
Net Income | -19.9M | ↓ 24.99% |
Net Profit Margin | -22.04% | ↑ 13.13% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 94.6M | ↑ 4.9% |
Net Income | -13.3M | ↓ 33.23% |
Net Profit Margin | -14.03% | ↑ 8.01% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 21.6M | ↓ 6.75% |
Net Income | -6.9M | ↑ 5.09% |
Net Profit Margin | -31.84% | ↓ 3.59% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 24.3M | ↑ 12.46% |
Net Income | -17.8M | ↑ 159.65% |
Net Profit Margin | -73.5% | ↓ 41.66% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 21.5M | ↓ 11.33% |
Net Income | -4.7M | ↓ 73.75% |
Net Profit Margin | -21.76% | ↑ 51.74% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 21.8M | ↑ 1.26% |
Net Income | -3.2M | ↓ 31.43% |
Net Profit Margin | -14.73% | ↑ 7.03% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 23.6M | ↑ 8.22% |
Net Income | -4.6M | ↑ 42.96% |
Net Profit Margin | -19.47% | ↓ 4.74% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 27.7M | ↑ 17.5% |
Net Income | -786.0K | ↓ 82.88% |
Net Profit Margin | -2.84% | ↑ 16.63% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 155.5M | ↓ 16.5% |
Total Liabilities | 175.0M | ↑ 11.19% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 110.5M | ↓ 28.96% |
Total Liabilities | 117.2M | ↓ 33.04% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 103.4M | ↓ 6.38% |
Total Liabilities | 117.5M | ↑ 0.29% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 160.3M | ↑ 55.02% |
Total Liabilities | 118.3M | ↑ 0.63% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 157.4M | ↓ 1.79% |
Total Liabilities | 97.6M | ↓ 17.48% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 153.5M | ↓ 2.52% |
Total Liabilities | 94.8M | ↓ 2.84% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 151.3M | ↓ 1.36% |
Total Liabilities | 116.0M | ↑ 0.01% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 157.4M | ↑ 4.07% |
Total Liabilities | 97.6M | ↓ 15.91% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 149.9M | ↓ 4.77% |
Total Liabilities | 94.0M | ↓ 3.71% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 148.7M | ↓ 0.8% |
Total Liabilities | 94.4M | ↑ 0.49% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 151.5M | ↑ 1.88% |
Total Liabilities | 93.3M | ↓ 1.21% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 153.5M | ↑ 1.28% |
Total Liabilities | 94.8M | ↑ 1.65% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -43.1M | ↑ 152.99% |
Investing Cash Flow | -7.1M | ↓ 31.33% |
Financing Cash Flow | 27.7M | ↑ 16.22% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -25.5M | ↓ 40.86% |
Investing Cash Flow | -9.9M | ↑ 39.21% |
Financing Cash Flow | 16.0M | ↓ 42.33% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 8.1M | ↓ 131.64% |
Investing Cash Flow | -7.6M | ↓ 22.89% |
Financing Cash Flow | 4.1M | ↓ 74.06% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 10.9M | ↑ 34.6% |
Investing Cash Flow | -29.3M | ↑ 285.26% |
Financing Cash Flow | 19.9M | ↑ 379.51% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -3.6M | ↓ 133.56% |
Investing Cash Flow | -8.4M | ↓ 71.49% |
Financing Cash Flow | 1.8M | ↓ 91.09% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 473.0K | ↓ 75.98% |
Investing Cash Flow | -2.3M | ↑ 44.49% |
Financing Cash Flow | -2.1M | ↑ 1145.78% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 2.0M | ↑ 321.56% |
Investing Cash Flow | -2.7M | ↑ 18.49% |
Financing Cash Flow | 4.2M | ↓ 301.16% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -2.9M | ↓ 243.08% |
Investing Cash Flow | -3.4M | ↑ 23.39% |
Financing Cash Flow | -2.5M | ↓ 159.45% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 1.2M | ↓ 142.94% |
Investing Cash Flow | -2.1M | ↓ 36.58% |
Financing Cash Flow | -674.0K | ↓ 72.75% |
Sell
Neutral
Buy
Societal Cdmo Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|
First Light Asset Management, LLC
Samjo Capital, LLC
Awm Investment Company Inc
Driehaus Capital Management LLC
Royce & Associates, LP
Samjo Management LLC
recro gainesville, llc, provides solid dosage form development, clinical and commercial manufacturing, and packaging and logistics services to the global pharmaceutical market. specializing in extended release solid dose and dea controlled substances, recro has the experts to deliver clients’ most complex pharmaceutical development and manufacturing projects in its best-in-class, 97,000-square-foot manufacturing facility. for more information about recro’s flexible cdmo solutions, visit www.recrogainesville.com
Organization | Societal Cdmo Inc |
Employees | 258 |
CEO | Mr. Wayne B. Weisman J.D. |
Industry | Miscellaneous |
A Spac I Acquisition Corp
$1.10
+0.0%
Keyarch Acquisition Corp
$1.10
+0.0%
Connexa Sports Technologies Inc
$1.10
+0.0%
Us Value Etf
$1.10
+0.0%
First Wave Biopharma Inc
$1.10
+0.0%
Global X Msci Next Emerging
$1.10
+0.0%
Fat Projects Acquisition Corp
$1.10
+0.0%
Capital Link Global Fintech
$1.10
+0.0%
Applied Uv Inc
$1.10
+0.0%